12 research outputs found
Natural History and Outcome of Hepatic Vascular Malformations in a Large Cohort of Patients with Hereditary Hemorrhagic Teleangiectasia
BACKGROUND: Hereditary hemorrhagic telangiectasia is a genetic disease characterized by teleangiectasias involving virtually every organ. There are limited data in the literature regarding the natural history of liver vascular malformations in hemorrhagic telangiectasia and their associated morbidity and mortality.
AIM: This prospective cohort study sought to assess the outcome of liver involvement in hereditary hemorrhagic telangiectasia patients.
METHODS: We analyzed 16 years of surveillance data from a tertiary hereditary hemorrhagic telangiectasia referral center in Italy. We considered for inclusion in this study 502 consecutive Italian patients at risk of hereditary hemorrhagic telangiectasia who presented at the hereditary hemorrhagic telangiectasia referral center and underwent a multidisciplinary screening protocol for the diagnosis of hereditary hemorrhagic telangiectasia. Of the 502 individuals assessed in the center, 154 had hepatic vascular malformations and were the subject of the study; 198 patients with hereditary hemorrhagic telangiectasia and without hepatic vascular malformations were the controls. Additionally, we report the response to treatment of patients with complicated hepatic vascular malformations.
RESULTS: The 154 patients were included and followed for a median period of 44 months (range 12-181); of these, eight (5.2%) died from VM-related complications and 39 (25.3%) experienced complications. The average incidence rates of death and complications were 1.1 and 3.6 per 100 person-years, respectively. The median overall survival and event-free survival after diagnosis were 175 and 90 months, respectively. The rate of complete response to therapy was 63%.
CONCLUSIONS: This study shows that substantial morbidity and mortality are associated with liver vascular malformations in hereditary hemorrhagic telangiectasia patients
Lymphangioma of the maxillary sinus
Lymphangioma’s localization in paranasal sinus is rare, but should be consider in the differential diag- nosis of the disorders of this region.
Surgeons and pathologists should be aware of the occur- rence of these lesions in such rare anatomical locations for prompt diagnosis and early treatment
MOLECULAR REGULATION OF LIVER GRAFT CHOLESTEROL METABOLISM AFFECTS THE OUTCOME OF HUMAN LIVER TRANSPLANTATION
MOLECULAR STUDY OF HEPATOCELLULAR CHOLESTEROL HOMEOSTASIS IN HUMAN LIVER TRANSPLANTATION
REGULATION OF LIVER GRAFT CHOLESTEROL SYNTHESIS AND UPTAKE AFFECTS THE OUTCOME OF HUMAN LIVER TRANSPLANTATION
RECIPIENT MTHFR C677T POLYMORPHISM PREDICTS PRE-TRANSPLANT CIRRHOSIS PROGRESSION AND SURVIVAL AFTER LIVER TRANSPLANTATION
RECIPIENT MTHFR C677T POLYMORPHISM PREDICTS PRE-TRANSPLANT CIRRHOSIS PROGRESSION AND SURVIVAL AFTER LIVER TRANSPLANTATION
RECIPIENT MTHFR C677T POLYMORPHISM PREDICTS PRE-TRANSPLANT CIRRHOSIS PROGRESSION AND SURVIVAL AFTER LIVER TRANSPLANTATION
Differential vascular endothelial growth factor A protein expression between small hepatocellular carcinoma and cirrhosis correlates with serum vascular endothelial growth factor A and alpha-fetoprotein.
Drugs with antivascular endothelial growth factor A (anti-VEGF-A) action are under clinical evaluation with encouraging results in advanced hepatocellular carcinoma (HCC). The relative VEGF-A protein expression in non-advanced HCC and in the cirrhotic non-tumoral tissue in the same patient, a variable that could be important for treatment efficacy, has been investigated with conflicting results, only using the cirrhotic tissue surrounding the neoplasm (CS). We measured, for the first time, VEGF-A expression in non-advanced HCC and in the respective CS and cirrhotic tissue at a distance from the tumour (CD), in 24 patients who underwent liver transplantation. VEGF-A protein was more expressed (P<0.05) in HCC than in CD, while no difference was found between HCC and CS. In HCC patients with a serum alpha-fetoprotein (AFP) higher than 20 ng/ml, VEGF-A protein expression in HCC was higher than in the corresponding CD in 83% of cases and AFP and serum VEGF-A corrected for the platelet count positively correlated with the differential VEGF-A protein expression between HCC and CD. Our data provide a rationale for clinical trials involving anti-VEGF-A treatments in patients with non-advanced HCC, and suggest that serum AFP and VEGF-A are variables to be taken into account in these studies